LRIG3 modulates proliferation, apoptosis and invasion of glioblastoma cells as a potent tumor suppressor

Journal of the Neurological Sciences

Volumn 350, Issue 1-2, 2015, Pages 61-68

  Guo, Dongsheng ^a   Yang, Hongkuan ^a   Guo, Yang ^a   Xiao, Qungen ^a   Mao, Feng ^a   Tan, Yihu ^a   Wan, Xueyan ^a   Wang, Baofeng ^a   Lei, Ting ^a  

^a Tongji Hospital   (China)

Author keywords

Apoptosis; EGFR; Glioblastoma; Invasion; LRIG3; Proliferation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; EGFR PROTEIN, HUMAN; LRIG3 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; LEUCINE RICH REPEATS AND IMMUNOGLOBULIN LIKE DOMAINS 3 GENE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG SCREENING; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PREVENTION AND CONTROL; PROCEDURES; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84933179190     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2015.02.015     Document Type: Article

References (28)

1. Dreyfuss JM, Johnson MD, Park PJ. Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer 2009;8:71.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
4. De Long CM, Bragg R, Simmons JA. Evidence for spatial representation of object shape by echolocating bats (Eptesicus fuscus). J Acoust Soc Am 2008;123:4582-98.
5. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21: 2683-710.
6. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009;100:2235-41.
7. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
8. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004;23: 3270-81.
9. Wang B, Han L, Chen R, Cai M, Han F, Lei T, et al. Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro. Cancer Biol Ther 2009;8:1018-23.
10. Wong VW, Stange DE, Page ME, Buczacki S, Wabik A, Itami S, et al. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol 2012;14:401-8.
11. Zhao H, Tanegashima K, Ro H, Dawid IB. Lrig3 regulates neural crest formation in Xenopus by modulating Fgf and Wnt signaling pathways. Development 2008;135: 1283-93.
12. Abraira VE, Satoh T, Fekete DM, Goodrich LV. Vertebrate Lrig3-ErbB interactions occur in vitro but are unlikely to play a role in Lrig3-dependent inner ear morphogenesis. PLoS One 2010;5:e8981.
13. Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H, et al. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol 2006; 111:238-46.
14. Holmlund C, Haapasalo H, Yi W, Raheem O, Brannstrom T, Bragge H, et al. Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology 2009;29:242-7.
15. Lindquist D, Kvarnbrink S, Henriksson R, Hedman H. LRIG and cancer prognosis. Acta Oncol 2014;53:1135-42.
16. Cai M, Han L, Chen R, Ye F, Wang B, Han F, et al. Inhibition of LRIG3 gene expression via RNA interference modulates the proliferation, cell cycle, cell apoptosis, adhesion and invasion of glioblastoma cell (GL15). Cancer Lett 2009;278:104-12.
17. Yang H, Mao F, Zhang H, Wang B, Wan F, Guo D, et al. Effect of over-expressed LRIG3 on cell cycle and survival of glioma cells. J Huazhong Univ Sci Technolog Med Sci 2011;31:667-72.
18. Cui RR, Mao DA, Yi L, Wang C, Zhang XX, Xie H, et al. Apelin suppresses apoptosis of human vascular smooth muscle cells via APJ/PI3-K/Akt signaling pathways. Amino Acids 2010;39:1193-200.
19. Mao F, Wang B, Xiao Q, Xi G, Sun W, Zhang H, et al. A role for LRIG1 in the regulation of malignant glioma aggressiveness. Int J Oncol 2013;42:1081-7.
20. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75:181-9.
21. Wang Y, Moncayo G, Morin Jr P, Xue G, Grzmil M, Lino MM, et al. Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene 2013;32:872-82.
22. Ye F, Gao Q, Xu T, Zeng L, Ou Y, Mao F, et al. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. J Neurooncol 2009;94: 183-94.
23. Xie R, Yang H, Xiao Q, Mao F, Zhang S, Ye F, et al. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation. Oncol Rep 2013;29:177-84.
24. Xiao Q, Tan Y, Guo Y, Yang H, Mao F, Xie R, et al. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the fulllength LRIG2. PLoS One 2014;9:e111419.
25. Wang Y, Poulin EJ, Coffey RJ. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer 2013;108:1765-70.
26. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 2010;9:592-603.
27. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501.
28. Rafidi H, Mercado III F, Astudillo M, Fry WH, Saldana M, Carraway III KL, et al. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3). J Biol Chem 2013;288:21593-605.